[1] Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis 2015;9(4):e0003709. https://doi.org/10.1371/journal.pntd.0003709.
[2] CDC. National notifiable infectious diseases surveillance. https://www.chinacdc.cn/jksj/jksj01/. [2006-1-1]. (In Chinese).
[3] Chinese Center for Disease Control and Prevention. Technical guidelines for human rabies prevention and control (2016). Chin J Viral Dis 2016;6(3):161 − 88. https://doi.org/10.16505/j.2095-0136.2016.03.001.
[4] General Department of the National Bureau of Disease Control and Prevention, General Office of the National Health Commission. Guidelines for the rabies postexposure prevention and disposal (2023 edition). Chin J Viral Dis 2024;14(1):22 − 4. https://doi.org/10.16505/j.2095-0136.2024.1003.
[5] de Melo GD, Hellert J, Gupta R, Corti D, Bourhy H. Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. Curr Opin Virol 2022;53:101204. https://doi.org/10.1016/j.coviro.2022.101204.
[6] Fan LL, Zhang L, Li JX, Zhu FC. Advances in the progress of monoclonal antibodies for rabies. Hum Vaccin Immunother 2022;18(1):2026713. https://doi.org/10.1080/21645515.2022.2026713.
[7] World Health Organization. Rabies vaccines: WHO position paper, April 2018 - Recommendations. Vaccine 2018;36(37):5500 − 3. https://doi.org/10.1016/j.vaccine.2018.06.061.
[8] Liu C, Lv XJ, Liu S, Chen QJ, Zhu ZG, Yu R, et al. Research trends in anti-rabies virus monoclonal antibody: a bibliometric analysis. Hum Vaccin Immunother 2025;21(1):2508559. https://doi.org/10.1080/21645515.2025.2508559.
[9] Sparrow E, Torvaldsen S, Newall AT, Wood JG, Sheikh M, Kieny MP, et al. Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline. Vaccine 2019;37 Suppl 1:A132-9. http://dx.doi.org/10.1016/j.vaccine.2018.11.004.
[10] Wang XQ, Zha YX, Wang ZX, Jiang Y, Zhang XY, Guo JS, et al. Effects of Zamerovimab/Mazorelvimab on the rabies virus neutralizing antibody level in the grade Ⅲ rabies post exposure subjects. Chin J Exp Clin Virol 2024;38(4):388 − 94. https://doi.org/10.3760/cma.j.cn112866-20240624-00097.
[11] Müller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009;3(11):e542. https://doi.org/10.1371/journal.pntd.0000542.
[12] Chao TY, Ren SQ, Shen EY, Moore S, Zhang SF, Chen L, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis 2017;11(12):e0006133. https://doi.org/10.1371/journal.pntd.0006133.
[13] Lyu XJ, Dong GM, Liu XQ, Liu S, Chen C, Chen QJ, et al. Progress and prospect of clinical application of anti-rabies virus monoclonal antibody preparation. Natl Med J China 2023;103(32):2475 − 9. https://doi.org/10.3760/cma.j.cn112137-20230307-00341.
[14] Cabasso VJ, Loofbourow JC, Roby RE, Anuskiewicz W. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ 1971;45(3):303-15. https://pubmed.ncbi.nlm.nih.gov/5316911/.
[15] Liu XQ, Li YF, Li JY, Zhou JM, Guo JS, Pu Y, et al. Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: a phase III, randomized, double-blind, non-inferiority trial. Int J Infect Dis 2023;134:53 − 62. https://doi.org/10.1016/j.ijid.2023.05.017.
[16] Scholand SJ, Quiambao BP, Rupprecht CE. Time to revise the WHO categories for severe rabies virus exposures-category IV? Viruses 2022;14(5):1111. http://dx.doi.org/10.3390/v14051111.
[17] Ledesma LA, Lemos ERS, Horta MA. Comparing clinical protocols for the treatment of human rabies: the Milwaukee protocol and the Brazilian protocol (Recife). Rev Soc Bras Med Trop 2020;53:e20200352. https://doi.org/10.1590/0037-8682-0352-2020.
[18] Christensen M, Sparre-Ulrich AH, Hartmann B, Grevstad U, Rosenkilde MM, Holst JJ, et al. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int J Obes 2015;39(11):1651 − 4. https://doi.org/10.1038/ijo.2015.136.
[19] de Melo GD, Sonthonnax F, Lepousez G, Jouvion G, Minola A, Zatta F, et al. A combination of two human monoclonal antibodies cures symptomatic rabies. EMBO Mol Med 2020;12(11):e12628. https://doi.org/10.15252/emmm.202012628.